280E for Infuser Organizations
Licensed infusers are producers under the tax code, and the capitalizable cost pool is wide: input biomass and distillate, solvents, terpenes, hardware and packaging, extraction and infusion labor with its burden, equipment depreciation, controlled-environment booth or kitchen occupancy, production utilities and in-process QC. All of that lands in inventory and reaches the return through COGS.
Sales commissions, brand spend, executive salaries and office overhead stay outside inventory and remain disallowed federally. Infusers who lump everything into the production cost pool risk the legitimate portion right alongside the aggressive portion — the opposite of what they're trying to accomplish.
Because conversion cost is such a large chunk of total cost here, even modest gains in yield or throughput translate directly into a lower unit cost and, once 280E is applied, a noticeably better after-tax result than the same efficiency gain would deliver at a retail counter.
- Capitalizable: materials, production labor, conversion overhead, packaging, QA
- Disallowed federally: selling, brand, executive and general administration
- Allocate using: machine hours, labor hours, unit counts, measured square footage
Standard Costing and BioTrack for Manufacturers
Every SKU needs a bill of materials and a standard cost, with actuals compared against it each period. Variance breaks into four separate problems — input price, biomass usage, extraction yield, labor efficiency — each with its own owner. Skip the standards and a margin swing has no explanation attached to it.
In BioTrack, manufacturing shows up as a chain of package transformations: inputs get consumed, a production batch forms, and finished packages get tagged. The books should mirror that same chain through work in process, so any batch still open at period end carries a real valuation instead of a guess. Failed runs and destruction events belong in both the compliance log and the ledger, with normal loss absorbed into good units and abnormal loss expensed outright.
Co-manufacturing and white-label deals with an unlicensed brand need explicit treatment up front. If the brand owns the material, it's service revenue and the material never touches the infuser's inventory; if the infuser buys its own inputs and sells finished goods under its own license, it's product revenue with full inventory accounting behind it.
Planning Priorities for Infusers
For infusers, planning is mostly a cost-system exercise — build the bill of materials correctly, document the allocations, keep BioTrack reconciled, and the federal position mostly takes care of itself. Layered on top of that: equipment purchase timing, capacity decisions on whatever asset is the bottleneck, and the Illinois subtraction modification that makes the state return diverge sharply from the federal one — worth confirming with an advisor each year for current applicability.
Our approach starts with the accounting system, and the tax return follows from it — not the other way around. If you hold an Illinois license for a infusion facility, a diagnostic review will show you exactly what your current setup is costing you before you commit to anything.
